Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 24:9:F1000 Faculty Rev-294.
doi: 10.12688/f1000research.20805.1. eCollection 2020.

Ulcerative colitis: Recent advances in the understanding of disease pathogenesis

Ross J Porter  1 , Rahul Kalla  1 , Gwo-Tzer Ho  1
Affiliations
Review

Ulcerative colitis: Recent advances in the understanding of disease pathogenesis

Ross J Porter et al. F1000Res. .

Abstract

Inflammatory bowel diseases are common, complex, immune-mediated conditions with a sharply rising global prevalence. While major advances since 2000 have provided strong mechanistic clues implicating a de-regulation in the normal interaction among host genetics, immunity, microbiome, and the environment, more recent progress has generated entirely new hypotheses and also further refined older disease concepts. In this review, we focus specifically on these novel developments in the pathogenesis of ulcerative colitis.

Keywords: Inflammation; Inflammatory Bowel Disease; Mucosal Immunology; Pathogenesis; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. General factors associated with increased susceptibility of UC.
CD, Crohn’s disease; UC, ulcerative colitis.
Figure 2.
Figure 2.. Molecular mechanisms involved in the development of mucosal inflammation in UC.
DAMPs, damage-associated molecular patterns; ER, endoplasmic reticulum; HLA, human leukocyte antigen; IL, interleukin; Mɸ, macrophage; NSAID, non-steroidal anti-inflammatory drug; OSM, oncostatin M; ROS, reactive oxygen species; SCFA, short-chain fatty acid; TNF, tumour necrosis factor; UC, ulcerative colitis.
See this image and copyright information in PMC

References

    1. Ng SC, Shi HY, Hamidi N, et al. : Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390(10114):2769–78. 10.1016/S0140-6736(17)32448-0 - DOI - PubMed

    2. F1000 Recommendation

    1. Jones GR, Lyons M, Plevris N, et al. : IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut. 2019;68(11):1953–60. 10.1136/gutjnl-2019-318936 - DOI - PMC - PubMed
    1. Kaplan GG: The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. 10.1038/nrgastro.2015.150 - DOI - PubMed
    1. Mulder DJ, Noble AJ, Justinich CJ, et al. : A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis. 2014;8(5):341–8. 10.1016/j.crohns.2013.09.009 - DOI - PubMed
    1. Mahid SS, Minor KS, Soto RE, et al. : Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–71. 10.4065/81.11.1462 - DOI - PubMed

Publication types